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Abstract The role of the Polycomb group gene Bmi1 in
proliferation control of lymphoid and neuronal progenitors
as well as in self-renewal of haematopoietic and neural
stem cells has been recently demonstrated. Here we review
these recent findings with particular regard to their im-
plications for central nervous system development and
tumorigenesis.
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Introduction
During development, defined genetic programmes influ-
ence tissue-specific patterning by regulating gene expression
profile. This regulation involves the stable maintenance
of either an active or repressed state of expression of ho-
meotic genes by epigenetic mechanisms. Polycomb group
(PcG) genes regulate gene expression by forming large mul-
tiprotein complexes at specific chromosomal sites called
polycomb response elements (PREs), leading to chromatin
remodelling. Among the main targets of PcG members are
homeobox genes (Hox), which regulate several key devel-
opmental processes such as differentiation and patterning.
The first functional PcG member identified was B cell-
specific Moloney murine leukaemia virus integration site 1
(Bmi1) gene, a homologue of the Drosophila PcG protein
Posterior sex combs (Psc) [5]. It encodes for a 45-kDa
nuclear protein that is widely expressed, e.g. in embryonic
stem cells, placenta, thymus, heart, testis and brain [25].
Ablation of the Bmi1 gene in mice leads to skeletal,
neural and haematopoietic abnormalities [23], the latter
characterised by severe hypoplasia of spleen and thymus
and highly reduced haematopoietic cell counts in the bone
marrow. Moreover, Bmi1-deficient bone marrow cells showed
an impaired proliferative response to mitogens, especially
cytokine IL-7, resulting in an abnormal expansion of com-
mitted B-cell precursors [23] and impaired self-renewing
capacity of haematopoietic stem cells (HSCs) [18].
These haematopoietic abnormalities were dramatically
rescued in Bmi1/INK4a double-knockout mice, provid-
ing evidence that INK4a locus is an in vivo downstream
target of Bmi1 [10]. Identification of the INK4a locus as
a target of Bmi1, which in turn is a critical regulator of
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the p53 and Rb tumor suppressor pathways, points to a
role of Bmi1 as a determining factor in cell cycle con-
trol. Because both pathways are frequently deregulated
in human cancer, altered expression of Bmi1 might be
involved in tumor formation as well.
The first evidence of the critical role of Bmi1 in tu-
morigenesis was provided by the development of T- and B-
cell lymphomas in transgenic mice overexpressing Bmi1
under control of the Eμ promoter [3, 8]. Conversely, the
proliferative potential and self-renewing capacity of leu-
kaemic stem cells lacking Bmi1 is compromised [13],
therefore pointing to a crucial role of Bmi1 in controlling
the proliferation of neoplastic haematopoietic cells. The
onset of B-cell lymphomas in Eμ-Bmi1 transgenic mice
was accelerated by overexpression of c-Myc, thus es-
tablishing a collaboration between the Bmi1 and c-Myc
oncogenes, mainly due to inhibition of Myc-mediated in-
duction of p19ARF and apoptosis [11].
In humans, overexpression of BMI1 was found in high-
grade B-cell non-Hodgkin lymphomas (NHLs) [4], breast
carcinoma [6], non-small cell lung cancer (NSCLC) [26]
and, most recently, in most human colorectal cancers [12].
Various studies examining expression levels of BMI1 in
relation to expression of other PcG genes in tumors have
suggested the coordinated action of the different polycomb
complexes in gene regulation. Deregulated expression of
the PcG complex subunits results in abnormal formation
of the PcG members and may contribute to tumorigenesis.
For example, functional antagonism between Bmi1 and
eed has been shown to regulate haematopoietic cell pro-
liferation. Similarly, in B-cell NHL, it was proposed that
BMI1 expression may be regulated by a second PcG com-
plex (ENX/EZH2/EED), which opposes the action of the
BMI1-containing PcG complex, suggesting that the dis-
turbances in the equilibrium of PcG complexes may con-
tribute to altered cellular behaviour [24].
Failure to down-regulate BMI1 in proliferating neoplas-
tic cells may play a role in the pathogenesis of the tumors,
but mechanisms leading to BMI1 overexpression are un-
clear. Gene amplification of oncogenes is a common
mechanism of tumor induction, however, BMI1 gene am-
plification was observed only in a minority of mantle cell
lymphomas with a corresponding increase in BMI1 protein
expression [4].
Apart from the role of Bmi1 in the haematopoietic sys-
tem (recently reviewed in [16, 22]), recent findings have
shed new light on its involvement in self-renewal of neural
stem cells (NSCs) and proliferation control of progenitor
cells during central nervous system (CNS) development
and possibly in formation of brain tumors.
Bmi1 and CNS development
The embryonic and postnatal development of the CNS
relies on complex and tightly regulated molecular mecha-
nisms that lead to a properly formed and functioning brain
through waves of proliferation and expansion of progenitor
cells and subsequent differentiation and migration of neu-
ronal and glial cells. However, it has become increasing-
ly evident that the adult brain is not a static structure but
retains some potential in plasticity and repair, which is due
not only to axonal growth and synapse remodelling but also
to the existence of multipotent NSCs.
The first indication of a possible role of Bmi1 in CNS
development came from the analysis of Bmi1-deficient
mice. In addition to haematopoietic and skeletal abnor-
malities, these mice develop neurological symptoms in-
cluding ataxia, seizures and tremors from 3 to 4 weeks after
birth [23]. Histopathological analysis revealed a normal
architecture of the brain but a significant reduction of the
overall size, which was particularly severe in the cerebel-
lum wherein reduced cellularity of the granular and mo-
lecular layers were most pronounced [10].
The formation of the cerebellum is quite a well-char-
acterised process occurring during the late embryonic and
early postnatal development. Granule neurons, the most
numerous cerebellar neurons, originate from a particular
structure of the metencephalon, known as the rhombic lip.
Granule cell progenitors migrate from the rhombic lip
along the outer surface of the cerebellar anlage to form the
external granular layer (EGL). Here they undergo clonal
expansion and, after exiting cell cycle, start their differen-
tiation process, which will eventually take them to the
internal granular layer (IGL) upon migrating along a grid of
glial cell processes. All other cerebellar neurons (Purkinje
neurons and molecular layer neurons) originate at differ-
ent time points from the ventricular neuroepithelium of
the metencephalon.
Analysis of Bmi1 expression during cerebellar develop-
ment shows a widespread expression of the gene in cer-
ebellar progenitor cells, which is particularly strong in the
transiently amplifying granule cell progenitors located in
the EGL. Newborn Bmi1−/−mice display a reduced number
of immature EGL granule cell precursors, as identified by
expression of the HLH gene Math-1 and an increased
number of postmitotic EGL granule cell precursors ex-
pressing the cyclin-dependent kinase inhibitor (CDKi) p27.
Moreover, the postnatal clonal expansion of these progen-
itor cells was hampered and was accompanied by an
increased rate of apoptosis. The identification of Bmi1 as a
downstream target of the Shh pathway, a signalling path-
way essential for controlling the proliferation of EGL
progenitor cells during development, provides an interpre-
tation frame for these findings [14]. Indeed, granule cell
progenitors lacking Bmi1 are less responsive to induction
of proliferation by Shh in vitro [14].
During development of the CNS, NSCs give rise to re-
stricted progenitor cells, which differentiate into neuronal
and glial cells. Some stem cells still exist in certain regions
of the adult brain, namely, the subventricular zone (SZV) of
the lateral ventricle in the cortex and the subgranular zone
of the hippocampus.
Recently, Bmi1 was shown to be required for the self-
renewal of NSCs of the telencephalon and of the peripheral
nervous system, but absence of Bmi1 did not impair either
the survival of NSCs or the proliferation of restricted neural
progenitors from the gut and forebrain. Indeed, Molofsky
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and colleagues [15] showed striking depletion of NSCs in
adult Bmi1−/− mice, but no defects in their survival and
differentiation. Moreover, Bmi1−/− glial progenitors, in-
duced to proliferate by neuregulin, showed a similar rate of
bromodeoxyuridine (BrdU) incorporation compared with
wild-type cells [15].
Lack of Bmi1, however, did affect the proliferation of
cerebellar granule cell progenitors. In contrast with all
other neurons of the CNS, which originate from the ven-
tricular neuroepithelium, the granule neurons of the cere-
bellum arise from a second germinal zone, the EGL. The
progenitor cells located in this layer undergo clonal expan-
sion during early postnatal development and by postnatal
day 20, most of the EGL cells would have differentiated
and migrated inwards to their final destination, the IGL. We
have recently shown that the level of Bmi1 expression
correlates with the proliferation status of granule cell pre-
cursors located in the EGL during clonal expansion:
Strongest Bmi1 expression was found between postnatal
days 5 and 8, at the peak of progenitor proliferation. The
absence of Bmi1 during this period leads to a significant
reduction of proliferating granule cell progenitors, which
demonstrates a crucial role of Bmi1 in the maintenance and
expansion of immature granule cell precursors. However,
the proliferation rate of other neuronal progenitors orig-
inating from the ventricular neuroepithelium was not
affected by the lack of Bmi1 [15].
These observations imply that Bmi1 is involved in the
control of proliferation of neural progenitor cells through
different mechanisms. One possibility would be that the
proliferation control varies among restricted progenitor
cells from different region of the CNS. According to this
hypothesis, proliferation of restricted neuronal progenitors
of the forebrain and of the gut would be independent of
Bmi1, whereas restricted granule cell precursors of the
cerebellum would need Bmi1 for efficient proliferation.
However, how sure are we that all EGL cells are restricted
progenitor cells, and how restricted are they really? It has
recently been shown that EGL precursor cells isolated
from the outermost proliferative zone of the EGL can be
induced to differentiate not only into granule neurons but
also into glial cells [17], therefore implying that they are
not yet irreversibly committed. It is conceivable that the
EGL contains not only committed progenitor cells but also
uncommitted cells or even stem cells, which are still de-
pendent on Bmi1 for their proliferation. On the other hand,
Bmi1-deficient cerebellar granule cell cultures lacking
Bmi1, proliferate less efficiently and are less responsive to
Shh-induced proliferation, thus suggesting that Bmi1 is at
least in part also involved in the proliferation control of
more committed progenitors.
The reduced cellularity of the molecular layer due to the
lack of stellate cells and of the majority of basket cells can
hardly be explained as a consequence of reduced numbers
of granule neurons. These neurons originate from another
germinal layer, the neuroepithelium (NE), and the overall
number of progenitor cells populating the NE of Bmi1
mutant mice is clearly reduced in the newborn cerebellum
[14], thus implying an impairment of self-renewal leading
to postnatal depletion in keeping with the observations of
Molofsky and colleagues [15]. It is intriguing that cross-
ing Bmi1-deficient mice with Ink4a/ARF mutant mice
leads to a significant rescue of the cerebellar phenotype
observed in the granular layer but has much less effect on
the reduced cellularity of the molecular layer ([10] and
S. Marino, unpublished observations). These observations
suggest that Bmi1 is involved in the control of proliferation
of neural progenitor cells through different mechanisms
(Fig. 1). In keeping with this hypothesis, the increase in
p16Ink4a expression contributed only in part to the reduc-
tion in self-renewal of Bmi1-deficient NSCs of the tel-
encephalon [15].
Partial restoration of cerebellar and NSC defects in an
Ink4a/ARF background implies that additional pathways
must exist in mediating Bmi1 functions in stem cell self-
renewal and progenitor proliferation in the CNS. It is con-
ceivable, for example, that Hox genes, which have been
described to be regulated by Bmi1, may be involved in the
process.
BMI1 and brain tumors
The up-regulation of Bmi1 expression during postnatal
clonal expansion of EGL progenitors and the impaired
proliferation of EGL cells lacking Bmi1 in vivo and in vitro
prompted us to check for overexpression of BMI1 in me-
dulloblastomas. These neoplasms are highly aggressive
embryonal tumors of childhood, developing from the un-
controlled proliferation of these very same progenitor cells.
BMI1 was found to be overexpressed in the majority of
human medulloblastoma analysed. Moreover, overexpres-
sion of BMI1 correlated with overexpression of PATCHED-1
(PTCH1), which is a reliable indicator of activation of the
Shh pathway [14]. The involvement of the Shh pathway in
the pathogenesis of medulloblastomas is well known;
however, only a minority of these tumors show mutations
of known members of the Shh pathway. Mutation analysis
of BMI1 at the DNA level will help to clarify if BMI1
might at least in part account for this difference.
Another aspect of the stronger growing link between
developmental processes and tumor formation has been
highlighted from recent data, suggesting the presence of
“stem cell-like” cancerous cells in blood, breast and brain
cancers (reviewed in [2, 19]). According to this theory,
only a relatively small fraction of cells in a given tumor
possesses the ability to proliferate and self-renew exten-
sively. These multipotent cancer cells have been called
“tumor stem cells” and have been shown to share many
properties with normal stem cells in that they can self-
renew and therefore be propagated for a prolonged time in
culture; moreover, they can be induced to express markers
of neuronal and glial lineages. So far, they have been
isolated from glioblastomas, high-grade glial tumors af-
fecting mainly middle-aged adults and from medulloblas-
tomas by two independent groups [7, 20, 21]. Whether
tumor stem cells represent a neoplastic transformation of
normal stem cells or of progenitor cells or even of dif-
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ferentiated cells that have regained some stem cell prop-
erties remains to be clarified. Recently, BMI1 expression
has been detected in cancerous stem cells, and withdrawal
of mitogen did not correlate with down-regulation of BMI1
expression in neurospheres derived thereof, as is the case
with neurospheres derived from non-neoplastic NSCs [9],
in agreement with a mitogen-independent proliferation of
neoplastic cells. The authors suggest that persistent high
level of BMI1 expression correlates with greater capacity
of self-renewal and might represent a general mechanism
contributing to tumorigenesis in the CNS. However, ad-
ditional studies are needed to demonstrate that also brain
tumors consist of cells organized in a hierarchy based on
their proliferation and differentiation capacity, as has been
shown for acute myeloid leukaemia and breast cancer.
Moreover, we did not observe significant overexpression of
BMI1 protein in the glioblastomas analysed, in keeping
with a more specific role of BMI1 in neoplastic transfor-
mation of EGL progenitor cells giving rise to medullo-
blastoma. However, it is also conceivable that lack of
significant overexpression of BMI1 in the glioblastomas
analysed simply reflects a more pronounced differentiation
of most cells constituting these tumors and does not
exclude the possibility that the cancerous stem cells indeed
express BMI1 in these tumors.
Overexpression of BMI1 in medulloblastoma and in
cancerous stem cells isolated from these and other brain
tumors is intriguing and might open new interesting ther-
apeutic options (reviewed in [1]). It should be stressed,
however, that additional studies such as selective overex-
pression of Bmi1 in mice are needed to prove the path-
ogenetic role of Bmi1 in the development of these
neoplasms.
Bmi1 -/- mice  
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Fig. 1 Role of Bmi1 in stem cell self-renewal and progenitor
proliferation in the CNS. Upper panel: Bmi1 deficiency leads to
reduced self-renewal capacity of neural stem cells of the telenceph-
alon and consequently to their postnatal depletion. Restricted neural
progenitors from the forebrain proliferate normally in the absence of
Bmi1. p16Ink4a and p19arf are downstream effectors of Bmi1 re-
pression. Lower panel: In the cerebellum, Bmi1 plays an essential
role in the transient expansion of immature granule cell precursors
as a downstream player of the Shh pathway. Whether Bmi1 is crucial
for the proliferation of all granule cell precursors or only of a subset
of them (neural stem cell?) is unclear
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